Akero Therapeutics Statistics
Total Valuation
AKRO has a market cap or net worth of $1.94 billion. The enterprise value is $1.22 billion.
Important Dates
The last earnings date was Friday, November 8, 2024, before market open.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AKRO has 69.80 million shares outstanding. The number of shares has increased by 25.99% in one year.
| Current Share Class | 69.80M |
| Shares Outstanding | 69.80M |
| Shares Change (YoY) | +25.99% |
| Shares Change (QoQ) | +0.41% |
| Owned by Insiders (%) | 1.73% |
| Owned by Institutions (%) | 89.40% |
| Float | 54.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.66 |
| P/TBV Ratio | 2.67 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.25, with a Debt / Equity ratio of 0.05.
| Current Ratio | 17.25 |
| Quick Ratio | 16.57 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -61.69 |
Financial Efficiency
Return on equity (ROE) is -35.90% and return on invested capital (ROIC) is -24.33%.
| Return on Equity (ROE) | -35.90% |
| Return on Assets (ROA) | -23.17% |
| Return on Capital (ROIC) | -24.33% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.24M |
| Employee Count | 56 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +18.84% in the last 52 weeks. The beta is -0.24, so AKRO's price volatility has been lower than the market average.
| Beta (5Y) | -0.24 |
| 52-Week Price Change | +18.84% |
| 50-Day Moving Average | 30.65 |
| 200-Day Moving Average | 25.91 |
| Relative Strength Index (RSI) | 39.91 |
| Average Volume (20 Days) | 587,048 |
Short Selling Information
The latest short interest is 3.30 million, so 4.73% of the outstanding shares have been sold short.
| Short Interest | 3.30M |
| Short Previous Month | 3.29M |
| Short % of Shares Out | 4.73% |
| Short % of Float | 6.01% |
| Short Ratio (days to cover) | 5.51 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -269.27M |
| Pretax Income | -204.18M |
| Net Income | -237.22M |
| EBITDA | -269.27M |
| EBIT | -269.27M |
| Earnings Per Share (EPS) | -$3.74 |
Full Income StatementBalance Sheet
The company has $717.25 million in cash and $36.01 million in debt, giving a net cash position of $751.06 million or $10.76 per share.
| Cash & Cash Equivalents | 717.25M |
| Total Debt | 36.01M |
| Net Cash | 751.06M |
| Net Cash Per Share | $10.76 |
| Equity (Book Value) | 738.33M |
| Book Value Per Share | 10.61 |
| Working Capital | 703.60M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$211.64 million and capital expenditures -$999,000, giving a free cash flow of -$212.64 million.
| Operating Cash Flow | -211.64M |
| Capital Expenditures | -999,000 |
| Free Cash Flow | -212.64M |
| FCF Per Share | -$3.05 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |